This breakthrough enables Linea AI to intelligently analyze and contextualize all forms of content, including complex visual ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

In the complex pharmaceutical market, achieving high levels of brand memorability directly influences patient choices and adherence, making it a critical focus for marketing strategies.

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

MediWound Ltd. ( NASDAQ:MDWD ) is possibly approaching a major achievement in its business, so we would like to ...

Empowering labs with automated equipment that produces rich, traceable, and actionable data insights means pharmaceutical companies can ... next step of automated visual inspection, leading ...

Learn more about whether Charles River Laboratories International, Inc. or Stevanato Group S.p.A. is a better investment ...

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025Upon FDA approval, ...

As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with ...